论文部分内容阅读
目的：为探讨化疗与FMS癌基因突变及这种突变与继发性血病的关系．方法：收集50例妇科肿瘤病人外周血．其中35例为化疗前的外周血．15例为化疗后的外周血．应用半巢式PCR－SSCP技术检测其外用上白细胞FMS癌基因突变。情况。结果：35例未经化疗病人无FMS癌基因突变，而15例经化疗后病人中有1例（6．7％）发生FMS癌基因突变．结论：提示化疗药物可能引起FMS癌基因的突变．并进一步引起继发性白血病．检测化疗后肿瘤病人外用血FMS癌基因的突变将有助早期发现继发性白血病。
Objective: To investigate the relationship between chemotherapy and FMS oncogene mutations and the relationship between this mutation and secondary blood diseases. Methods: Collect peripheral blood of 50 patients with gynecological tumors. 35 of them were peripheral blood before chemotherapy. 15 cases were peripheral blood after chemotherapy. Semi-nested PCR-SSCP technique was used to detect the mutation of FMS oncogene in epidermal cells. Happening. Results: There were no FMS oncogene mutations in 35 patients without chemotherapy, and 1 out of 15 (6.7%) patients after chemotherapy had FMS oncogene mutations. Conclusion: It is suggested that chemotherapeutic drugs may cause mutations in the FMS oncogene. And further cause secondary leukemia. The detection of mutations in the FMS oncogene of tumor blood for cancer patients after chemotherapy will help early detection of secondary leukemia.